Prognostic Epigenetics

Shilpy Sharma

ኖቬም 2019 · Translational Epigenetics መጽሐፍ 15 · Academic Press

ኢ-መጽሐፍ

442

ገጾች

ብቁ

የተሰጡት ደረጃዎች እና ግምገማዎች የተረጋገጡ አይደሉም የበለጠ ለመረዳት

ስለዚህ ኢ-መጽሐፍ

This volume provides comprehensive information on how mapping an individual's epigenome can be medically relevant and holds the potential to improve preventive medicine and precision therapeutics at an early-stage (prior to disease onset). In order to advance clinical adoption of the recently developed epigenetic approaches, it is necessary for translational scientists, clinicians, and students to gain a better understanding about epigenetic mechanisms that are associated with a particular disorder; and to be able to effectively identify biomarkers that can be applied in drug development and for better diagnosis and prognosis of diseases. Prognostic Epigenetics is the most-inclusive volume to-date specifically dedicated to epigenetic markers that have been developed for prognosis of diseases, recent advances in this field, the clinical implementation of this research, and the future outlook. - Compiles all known information on prognostic epigenetics and its role in preventive medicine and drug discovery - Covers the basic functionality of epigenetic mechanisms involved in early disease prognosis and diagnosis, and provides tools for the identification and development of these biomarkers for a wide range of diseases - Enables clinicians, researchers, and pharmacologists to improve preventive medicine and precision therapeutics throughout a person's lifetime - Features chapter contributions from leading international researchers

ስለደራሲው

Dr. Shilpy Sharma, PhD, is an Assistant Professor at the Department of Biotechnology, Savitribai Phule Pune University (Formerly University of Pune) in Pune, Maharashtra, India. She has served as a Post-Doctoral Fellow in the Department of Pharmacology at University of Michigan and as a Post-Doctoral Fellow at the Department of Surgery, University of Chicago Medical Center. Dr. Sharma’s research focuses on identification of prognostic biomarkers for complex disorders including cancer, diabetes, and asthma; and infectious diseases.